ARDS — Aridis Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.22m
- $2.18m
- $3.09m
- 21
- 89
- 27
- 43
Annual cashflow statement for Aridis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.1 | -29.7 | -22.3 | -42.2 | -30.4 |
| Depreciation | |||||
| Non-Cash Items | 0.066 | 2.96 | 2.14 | 8.3 | 2.06 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.52 | 18.2 | -0.617 | 10.5 | -1.3 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -24.3 | -8.16 | -20.5 | -22.9 | -29.1 |
| Capital Expenditures | -0.677 | -0.174 | -0.367 | -0.53 | -0.082 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1 | 0 | — | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.68 | -0.174 | -0.367 | -0.53 | -0.082 |
| Financing Cash Flow Items | — | — | — | — | -2.83 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 25.1 | 4.99 | 8.68 | 34.7 | 14.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.859 | -3.34 | -12.2 | 11.3 | -14.4 |